Trivalent M-related protein as a component of next generation group A streptococcal vaccines.
- Author:
Harry S COURTNEY
1
;
Shannon E NIEDERMEYER
;
Thomas A PENFOUND
;
Claudia M HOHN
;
Adam GREELEY
;
James B DALE
Author Information
- Publication Type:Original Article
- Keywords: Streptococcus pyogenes; Vaccines; Virulence factors
- MeSH: Antibodies; Humans; Immune Sera; Peptides; Rabbits; Staphylococcal Protein A*; Streptococcal Vaccines*; Streptococcus pyogenes; Vaccines; Virulence; Virulence Factors
- From:Clinical and Experimental Vaccine Research 2017;6(1):45-49
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: There is a need to broaden protective coverage of M protein–based vaccines against group A streptococci (GAS) because coverage of the current 30-valent M protein vaccine does not extend to all emm types. An additional GAS antigen and virulence factor that could potentially extend vaccine coverage is M-related protein (Mrp). Previous work indicated that there are three structurally related families of Mrp (MrpI, MrpII, and MrpIII) and peptides of all three elicited bactericidal antibodies against multiple emm types. The purpose of this study was to determine if a recombinant form containing Mrp from the three families would evoke bactericidal antiserum and to determine if this antiserum could enhance the effectiveness of antisera to the 30-valent M protein vaccine. MATERIALS AND METHODS: A trivalent recombinant Mrp (trMrp) protein containing N-terminal fragments from the three families (trMrp) was constructed, purified and used to immunize rabbits. Anti-trMrp sera contained high titers of antibodies against the trMrp immunogen and recombinant forms representing MrpI, MrpII, and MrpIII. RESULTS: The antisera opsonized emm types of GAS representing each Mrp family and also opsonized emm types not covered by the 30-valent M protein–based vaccine. Importantly, a combination of trMrp and 30-valent M protein antiserum resulted in higher levels of opsonization of GAS than either antiserum alone. CONCLUSION: These findings suggest that trMrp may be an effective addition to future constructs of GAS vaccines.
